Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Brown Capital Management International All Company Fund 2024 Q1 Investor Letter | Buyside Digest

Back to Fund Profile (Brown Capital Management International All Company Fund)

Primary Source Intelligence • Q1 2024 Letter Analysis

Brown Capital Management International All Company Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Brown Capital Management International All Company Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+3.24%

Annualized+9.55%

Digest Analysis

Quick Take

"Brown Capital's International All Company Fund underperformed benchmarks in Q1 2024 despite strong contributions from Novo Nordisk's GLP-1 franchise and ASML's semiconductor equipment monopoly."

Executive Summary

Brown Capital Management's International All Company Fund returned 3.24% in Q1 2024, underperforming the MSCI ACWI ex-US index (4.81%) and MSCI EAFE (5.93%). The fund employs a team-based investment approach that integrates members from the Mid Company Team to enhance decision-making through diverse perspectives. Top contributors included Novo Nordisk, benefiting from strong GLP-1 drug demand in the expanding obesity market, and ASML, which maintains a monopoly in extreme ultra-violet lithography equipment critical for advanced semiconductor manufacturing. Key detractors were Temenos, facing short-seller concerns about accounting practices, and Grifols, dealing with leverage issues and corporate governance questions. The fund eliminated Dechra Pharmaceuticals following its acquisition and added Novonesis through a merger. The team continues to focus on Exceptional Growth Companies with dominant positions in mission-critical, large and growing markets, leveraging their collaborative research process to identify compelling investment opportunities.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The letter demonstrates moderate-to-high conviction through detailed analysis of specific holdings with clear investment theses. The manager provides substantial fundamental analysis for Novo Nordisk, ASML, Temenos, and Grifols, explaining competitive positions and market dynamics. However, the absence of position sizing information and the team-based approach with consensus decision-making moderates the conviction score from the high range.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The letter maintains a constructive but measured tone regarding market opportunities. While the manager discusses exciting growth prospects in specific holdings like Novo Nordisk's GLP-1 franchise and ASML's semiconductor dominance, there is no broad market commentary suggesting strong bullishness. The focus remains on individual company fundamentals rather than market-wide optimism.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

The fund maintained existing positions with no new additions during the quarter, suggesting a cautious approach to new deployment. The elimination of Dechra Pharmaceuticals was due to acquisition completion rather than active selling. The measured approach to integrating teams and deliberate positioning indicates moderate risk appetite without aggressive expansion.

Capital Deployment

48%

De-riskingDeploying

Net Neutral (48%)

No new positions were added during the quarter, and one position (Dechra) was eliminated due to acquisition completion. This represents minimal net activity with a slight reduction in position count. The manager emphasizes being deliberate and taking time with team integration, suggesting no urgency to deploy capital. This indicates neutral to slightly negative deployment activity.

Forward Guidance

10%

CautiousExpansionary

Cautious (10%)

The manager expresses no clear directional bias for future deployment. The emphasis on taking time to build team chemistry and being deliberate in integration suggests a patient, monitoring approach rather than active deployment intentions. No specific plans for adding positions or scaling existing ones are mentioned.

Language Signal

30%

BearishBullish

Bearish (30%)

The language is predominantly positive when discussing individual holdings, with terms like 'excited,' 'strong growth,' 'mission-critical,' and 'compelling opportunities.' However, this is balanced by acknowledgment of challenges with Temenos and Grifols, and the overall tone is analytical rather than euphoric. The positive language around specific companies outweighs the cautious elements.

Perceived Risk

25%

Low RiskElevated

Low Risk (25%)

Risk discussion is limited to company-specific issues rather than systemic concerns. The manager acknowledges challenges with Temenos (short-seller report, accounting concerns) and Grifols (leverage, governance issues) but treats these as manageable company-specific risks. No broader market, economic, or systemic risks are discussed, indicating relatively low perceived environmental risk.

Opportunity Density

45%

ScarceAbundant

Selective (45%)

The manager sees selective opportunities in specific areas, particularly in companies with dominant market positions in growing markets like GLP-1 drugs and semiconductor equipment. However, the fact that no new positions were added during the quarter and the emphasis on being deliberate suggests opportunities require careful evaluation rather than being abundant. The focus on integration and team building also suggests a measured approach to new opportunities.

Time Horizon

75%

Short-TermLong-Term

Decade+ (75%)

The letter emphasizes long-term thinking through multiple indicators: focus on Exceptional Growth Companies with sustainable competitive advantages, detailed discussion of multi-year market growth trajectories (obesity market doubling to $50 billion by 2028), and explicit reference to being 'long-term shareholders.' The team-based approach and emphasis on building chemistry for long-term collaboration further reinforces a patient, multi-year investment horizon.